Insuficiencia cardíaca y diabetes
DOI:
https://doi.org/10.47196/diab.v52i1.85Palabras clave:
obesidad, diabetes mellitus, insuficiencia cardíacaResumen
Cuando nos enfrentamos a la diabetes mellitus (DM) y a la insuficiencia cardíaca (IC) nos encontramos con dos patologías que presentan aspectos en común. Uno de ellos es la alta prevalencia que existe en la población general. A su vez, la DM se postula como un factor de riesgo independiente para el desarrollo de IC, no sólo por los efectos de la hiperglucemia sostenida sino por el conjunto de comorbilidades asociadas que elevan el riesgo de estos pacientes de desarrollar cardiopatía isquémica y fallo cardíaco.
El objetivo del presente estudio es realizar una revisión de la diabetes y la hiperglucemia como un fenómeno que promueve el desarrollo de insuficiencia cardíaca.
Citas
IDF Diabetes Atlas Seventh Edition, 2015.
Global report on diabetes. World Health Organization, 2016.
Blecker S, Park H, Katz DS. Association of HbA1c with hospitalization and mortality among patients with heart failure and diabetes. BMC Cardiovascular Disorders 2016; 16:99.
Ryde L, Grant P, Anker S, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal 2013; 34, 3035-3087.
Alpert A, Lavie C, Agrawal H, et al. Obesity and heart failure: epidemiology, pathophysiology, clinical manifestations, and management. Translational Research 2014; 164:1-12.
Etelvino GM, Peluso AA, Santos RA. New components of the renin-angiotensin system: alamandine and the mas-related G protein-coupled receptor D. Curr Hypertens Rep 2014; 16:433.
Sarfaraz A, Jasmina V, Leanne G, et al. Angiotensin (1-12): a chymase-mediated cellular angiotensin II substrate. Curr Hypertens Rep 2014; 16: 429.
Mandavia C, Annauya R, Demarco V , Sower R. Molecular and metabolic mechanisms of cardiac dysfunction in diabetes. Life Sci 2013 Mar 28; 92(11):601-8
Morales O, Estañ Y. Conceptos nuevos sobre el sistema renina angiotensina. Hipertens Riesgo Vasc 2010; 27:211-217.
Mendoza-Torres E, Oyarzun A, Mondaca-Ruff D, et al. ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension. Ther Adv Cardiovasc Dis 2015 Aug; 9(4):217-37.
Márquez-Salom G. From obesity to hypertension and type 2 diabetes mellitus: the continuous metabolic multifunctional damage. Revisalud Unisucre 2013; 1: 128-130.
Ferrario CM. Cardiac remodelling and RAS inhibition. Ther Adv Cardiovasc 2016; 10: 162-171.
Imo E, Brigit A, Mat JAP. Biomechanical factors as triggers of vascular growth. Cardiovascular Research 2013; 99: 276-283.
Grossman E, Messerli F. Hypertension and diabetes. Adv Cardiol 2008; 45:82-106.
Bell DS. Hypertension and diabetes: a toxic combination. Endocr Pract 2008; 14:1031-1039.
Sowers J, Epstein M. Diabetes, hypertension, and cardiovascular disease. An Update Hypertension 2001; 37:1053-1059.
Hall G. Tratado de fisiología médica. La Circulación.12ª edición. Student Consult. 2012.
Escudero E. Microcirculación coronaria: anatomía, fisiología y fisiopatología. Su implicancia en el estudio de la perfusión miocárdica con ecocontraste. FAC, 2001.
Besty B. The pathophysiology of cardiovascular disease and diabetes: beyond blood pressure and lipids. Diabetes Spectrum 2008; 21:160-165.
Takayuki M, Satoshi Y, Hidemichi K, Tetsuji M. Diabetic cardiomyopathy: pathophysiology and clinical features. Heart Fail Rev 2013; 18: 149-166.
Di Carli M, Bianco-Battles D, Landa M, et al. Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus. Circulation 1999; 100:813-819.
Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007; 115:387-397.
Gao Y, Lu B, Sun ML, et al. Comparison of atherosclerotic plaque by computed tomography angiography in patients with and without diabetes mellitus and with known or suspected coronary artery disease. Am J Cardiol 2015; 108: 809-13.
Low-Wang C, Hess C, Hiatt W, et al. Clinical update: cardiovascular disease in diabetes mellitus. Circulation 2016; 133:2459-2502.
Eberhard S, Michael E, Markolf H, Oliver S, Bernd S, Diethelm T. Clinical features and treatment of coronary heart disease in diabetes. John Wiley & Sons 2015.
Jeffrey J, Syracuse, Chaikof E. The pathogenesis of diabetic atherosclerosis. Springer Science, 2012.
Roberts K, Hevener L, Barnard J. Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr Physiol 2013 Jan; 3(1):1-58.
Bensellam M, Laybutt R, Jonas C. The molecular mechanisms of pancreatic b-cell glucotoxicity: recent findings and future research directions. Molecular and Cellular Endocrinology 2012; 364: 1-27.
Philipp E, Scherer L. The multifaceted roles of adipose tissue-therapeutic targets for diabetes and beyond: The 2015 Banting Lecture. Diabetes 2016; 65:1452-1461.
Lam D, LeRoith D. Metabolic syndrome. En: Comprehensive free Online Endocrinology Books. South Dartmouth. MDText.com, Inc., 2000.
Amaral N, Darlington O. Metabolic abnormalities of the heart in type II diabetes. Diabetes & Vascular Disease Research 2015; 12: 239-248.
Thang S, Lean M. A clinical perspective of obesity, metabolic syndrome and cardiovascular disease. Journal of the Royal Society of Medicine Cardiovascular Disease 2016; 5: 1-13.
Halla J, Carmo J, Silva A, et al. Obesity-induced hypertension interaction of neurohumoral and renal mechanisms. Circ 2015; 116:991-1006.
Pasquale-Perrone F, Paolillo S, Constanzo P, et al. The role of metabolic syndrome in heart failure. European Heart Journal, 2015.
Ravichandran R, Dale A, O’Shea M. Insulin resistance: metabolic mechanisms and consequences in the heart. American Heart Association 2012; 32:2068-2076.
Taegtmeyer H, Beauloye C, Harmancey R, Hue L. Insulin resistance protects the heart from fuel overload in dysregulated metabolic states. Am J Physiol Heart Circ Physiol 2013; 305: 1693-169-7.
Heiko B, Dale A. Molecular mechanisms of diabetic cardiomyophaty. Diabetologia 2014; 57: 660-671.
Thiere J. Insuficiencia cardíaca y diabetes. Rev Argent Cardiol 2006; 74:60-67.
Aroor A, Chirag H, Mandavia I, et al. Insulin resistance and heart failure: molecular mechanisms. Heart Fail Clin 2012; 8: 609-617.
Kok B, Brindley D. Myocardial fatty acid metabolism and lipotoxicity in the setting of insulin resistance. Heart Failure Clin 2012; 8: 643-661.
McMurray J, Adamopoulos S, Anker S, et al. Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardíaca aguda y crónica 2012. Rev Esp Cardiol 2012; 65:.e1-e59.
Barisani L, Fernández A, Fairman E, et al. Consenso de diagnóstico y tratamiento de la insuficiencia cardíaca crónica. Rev Argent de Cardiol 2010; 78: 166-181.
Ponikowski P, Voors A, Anker S, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2016.
Borlaug B. Clinical manifestations and diagnosis of heart failure with preserved ejection fraction.UpToDate 2018
McKelvie R, Gordon W, Ezekowitz J, et al. The 2012 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: focus on acute and chronic heart failure. Canadian Journal of Cardiology 2009; 29:168-181.
Joso B, Neva B, et al. Silent ischemia and diabetes mellitus. Diabetologia Croatica 2010; 39-2.
Domanski M, Krause H, Deedwania P, et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol 2012; 2: 914-22.
Gullion C, Koro C, Ephross S, et al. The incidence of congestive heart failure in type 2 diabetes an update. Diabetes Care 2004; 27:1879-1884.
Botta E. Insuficiencia cardíaca y diabetes: una combinación de alto riesgo. Rev Ins Car 2009; 4:107-113.
Lawrence H, Young M, Frans J. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: The DIAD Study: a randomized controlled trial. JAMA 2009; 301: 1547-1555.
American Diabetes Association Standards of Medical Care in Diabetes. 2018
Lièvre M, Moulin P, Thivole C. Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-analysis assessing the effectiveness of systematic screening. Bio Med Central 2011; 12:23.
Jørgensen P, Jensen M, Mogelvang R, et al. Abnormal echocardiography in patients with type 2 diabetes and relation to symptoms and clinical characteristics. Diabetes & Vascular Disease Research 2016. Reprints and permissions: sagepub.co.uk/journals Permissions.nav, 2016.
Sherif F, Smiseth O, Appleton C, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2016; 29:277-314.
Shinder D, Kosis J, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry. The American Journal of Cardiology 1996; 77:1017-1020.
Domanski M, Krause-Steinrauf H, Deedwania P, et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol 2003; 42:914-922.
McMurray J, Packer M, Desai A, et al. Angiotensin-neprilysin inhibition vs enalapril in heart failure. N Engl J Med 2014; 371:993-1004.
Kristensen L, Preiss D, Jhund P, et al. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail 2016 Jan; 9(1).
Ferranini E, DeFronzo R. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. European Heart Journal 2015; 36:2288-2296.
Tahrani A, Barnett A, Bailey C. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol 2016 Oct; 12(10):566-92.
Luke A, Wan Z. The HbA1c and all-cause mortality relationship in patients with type 2 diabetes is J-Shaped: a meta-analysis of observational studies. Rev Diabet Stud Summer 2014; 11: 138-152.
Eurich D, Weir D, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure systematic review of observational studies involving 34.000 patients. Circ Heart Fail 2013; 6:395-402.
Salpeter Sr, Greyber E, Pasternak GA. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus (Review). The Cochrane Collaboration 2010.
MacDonald MR, Eurich DT, Majumdar SR, et al. Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. Diabetes Care 2010; 33:1213-1218.
Dormandy J, Charbonnel B, Eckland D, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (Prospective Pioglitazone Clinical Trial In Macrovascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-89.
Marso S, Gibert D, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375:311-22.
Zinman B, Wanner C, Lachin J. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128.
Bruce S, M.B., Ch.B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377:644-657.
Rådholm K, Figtree G, Perkovic V, et al. Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 2018.
Currie CJ, Poole CD, Evans M, et al. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab 2013; 98:668-77.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
